Genentech CEO Ashley Magargee reflects on biotech origins and future amid growing startup ecosystem

Genentech’s founder story was revisited in a recent interview with CEO Ashley Magargee. She recalled how co‑founder Herbert Boyer was initially skeptical of a brief meeting with venture capitalist Robert Swanson, yet the two ended up sketching the company’s first plans on napkins in a bar.

Today, the South San Francisco campus that once housed a fledgling biotech firm is now surrounded by a wave of new companies, many started by Genentech alumni such as Denali Therapeutics, Alumis and Alector. Magargee highlighted how the industry has evolved from a speculative venture into a mature, cash‑rich sector with constant innovation.

Magargee said she tries to keep the culture casual while insisting on rigorous science and innovation. As the head of a half‑century‑old organization that serves as a key R&D engine for Roche, she sees her role as guiding the next generation of biotech breakthroughs while staying grounded in the company’s pioneering roots.